NHLBI Announces Interest in Omics-Related R01 Applications for RFA-HL-14-024 "Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01)"

Notice Number: NOT-HL-15-280

Key Dates
Release Date:   October 29, 2015

Related Announcements
NOT-HL-15-247
RFA-HL-14-024
NOT-OD-15-137    

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

Omic technologies are powerful tools to investigate the pathogenesis of diseases.  These studies are large-scale evaluations of genes, proteins, and metabolites to provide unbiased evaluation of complex biological mixtures.  Due to advances in technology, omic throughput capabilities have increased dramatically over the past decade.  These approaches could be utilized to address the scientific knowledge gaps in the progression of HIV-related heart, lung, and blood diseases and sleep disorders.

This Notice is to inform National Heart, Lung, and Blood Institute (NHLBI) applicants that the Institute is interested in accepting R01 applications for RFA-HL-14-024 that utilize omic approaches, such as genomics, transcriptomics, and proteomics, to define the pathophysiology (e.g., biomarkers, mechanisms, and signaling pathways) of HIV-related heart, lung, and blood diseases and sleep disorders.  Investigators could build and leverage biorepositories from HIV-infected populations and/or HIV-relevant animal models, as well as perform pathway analyses to elucidate the underlying metabolic changes and signaling mechanisms in disease progression.

R01 applications proposing omic approaches must conform to the requirements of, and be submitted under, RFA-HL-14-024.  These applications should also adhere to the published NIH Office of AIDS Research guidelines in NOT-OD-15-137.

Inquiries

Please direct all inquiries to:

Renee Wong, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-451-6808
Email: wongr2@nhlbi.nih.gov